World MS Day: National Policy Dialogue Adopts Landmark 10-Point Declaration Calling for Stronger Recognition of Invisible Disabilities in India
~Stakeholders urge reforms across disability certification, healthcare access, insurance, workplace inclusion and…
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and…
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and…
Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more…
Nokia Corporation – Managers’ transactions (Hanrahan)
May 31, 2026 06:00 ET | Source: Nokia Oyj Nokia CorporationManagers’ transactions31…
Crypto News Today: AlphaPepe Hits $1.38M Raised While Bitcoin Price Prediction Targets $250K
MONACO, May 30, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning…
![Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About](https://i1.wp.com/ml.globenewswire.com/Resource/Download/ae83c67f-909d-4427-80c0-3bc4826dfd96?w=420&resize=420,280&ssl=1 "Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About")
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
New York City, NY, May 30, 2026 (GLOBE NEWSWIRE) -- The global…
THE KILLERS ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI
Millions of fans from across the world tuned in to watch the…
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time…
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and…
